
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **October, 2018**

Commission File Number: **001-38480**

IMV Inc.

(Name of registrant)

130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMV Inc.

Date: October 9, 2018

By: /s/ Pierre Labbé
Name: Pierre Labbé
Title: Chief Financial Officer

Form 6-K Exhibit Index

**Exhibit
Number**

Document Description

99.1	News Release dated October 9, 2018. Presenting at Upcoming Investor Conferences.
----------------------	--

**FOR IMMEDIATE RELEASE****IMV Inc. to Present at Upcoming Investor Conferences**

Dartmouth, Nova Scotia; October 9, 2018 –IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that [Chief Executive Officer Frederic Ors](#) and [Chief Financial Officer Pierre Labbé](#) will present a corporate update at two upcoming investor conferences.

[BIO Investor Forum](#), San Francisco, CA

- **Date:** Thursday, October 18, 2018
- **Time:** 9:00 a.m. PT
- **Location:** The Elizabeth Room, Westin St. Francis
- A live webcast of the presentation will be accessible via the following URL:
<http://www.veracast.com/webcasts/bio/investorforum2018/15132412139.cfm>.

[Dawson James Small Cap Growth Conference](#), Jupiter, FL

- **Date:** Tuesday, October 30, 2018
- **Time:** 10:30 a.m. ET
- **Location:** Track 2 - Preserve Ballroom B, Wyndham Grand Jupiter Hotel
- A live webcast of the presentation will be accessible via the following URL:
<http://wsw.com/webcast/dawson4/imv/>.

Both webcasts will be archived for 90 days following the live presentation. A copy of the presentations will also be available on the [Events, Webcasts & Presentations](#) page of IMV's website: www.imv-inc.com.

About IMV

IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.

###

Contacts for IMV:

MEDIA

Mike Beyer, Sam Brown Inc.

T: (312) 961-2502 E: mikebeyer@sambrown.com

INVESTOR RELATIONS

Pierre Labbé, Chief Financial Officer

T: (902) 492-1819 E: info@imv-inc.com

Patti Bank, Managing Director, Westwicke Partners

O: (415) 513-1284

T: (415) 515-4572 E: patti.bank@westwicke.com
